Stock Market Reviews

RVMD (Revolution Medicines, Inc.) News

Get the latest news, insights, and market updates on RVMD (Revolution Medicines, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy
  REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been randomized in the RASolute 304 trial. RASolute 304 is a global, open-label, Phase 3 clinical trial evaluating the safety and efficacy of daraxonrasib, a RAS(ON) multi-selective inhibitor, in patients with resectable pancreatic ductal adenocarcinoma (PDAC) who have recei
  Dec 18, 2025 - $RVMD
• FDA Breakthrough Status For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD)
  Revolution Medicines has recently advanced daraxonrasib, its oral multi-selective RAS(ON) inhibitor, into a Phase III trial for metastatic pancreatic ductal adenocarcinoma and, in June 2025, received US FDA Breakthrough Therapy Designation for previously treated patients with KRAS G12-mutant disease. This regulatory milestone highlights Revolution Medicines’ emerging role in precision oncology, where targeting RAS-pathway mutations is becoming increasingly important for difficult-to-treat...
  Dec 11, 2025 - $RVMD
• Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight
  DelveInsight's Pancreatic Cancer Market Insights report includes a comprehensive understanding of current treatment practices, pancreatic cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
  Dec 10, 2025 - $RVMD
• Delphia Therapeutics Appoints Leading Cancer Expert Steve Kelsey, M.D., to Board of Directors
  CAMBRIDGE, Mass., December 09, 2025--Delphia Therapeutics, Inc. (Delphia), a biopharmaceutical company pioneering an innovative new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation, today announced the appointment of Stephen (Steve) Kelsey, M.D., MB ChB, FRCP, FRCPath to its board of directors. Dr. Kelsey is a highly-accomplished physician-scientist, oncologist and cancer drug developer and currently serves as president, r
  Dec 9, 2025 - $RVMD
• Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue?
  Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 5, 2025 - $RVMD
• This Oncology Stock Just Hit New All-Time Highs
  Revolution Medicines (RVMD) is trading at fresh all-time highs. RVMD exhibits strong technical momentum with a 100% technical “Buy” opinion from Barchart. Shares are up nearly 60% over the past year. Wall Street analysts are overwhelmingly bullish on RVMD, although sentiment is mixed across other platforms. Today’s Featured Stock Valued...
  Dec 4, 2025 - $RVMD
• Revolution Medicines (RVMD): Assessing Valuation After Recent 28% Monthly Share Price Surge
  Revolution Medicines (RVMD) has been catching attention, with shares moving up 3% in the past day and gaining 28% in the last month. Investors seem curious about what is fueling this change, especially given the biotech sector’s volatility. See our latest analysis for Revolution Medicines. Momentum around Revolution Medicines has been strong, with a 28% jump in share price over the past month capping a nearly 75% gain in the last quarter. This surge stands out, particularly in a sector known...
  Nov 7, 2025 - $RVMD
• Revolution Medicines Inc (RVMD) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...
  Revolution Medicines Inc (RVMD) reports significant progress in pancreatic cancer treatment despite increased R&D and net losses.
  Nov 6, 2025 - $RVMD
• Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
  RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.
  Nov 6, 2025 - $RVMD
• Revolution Medicines (RVMD) Earnings Transcript
  At Revolution Medicines, Inc., we are tireless in our commitment to revolutionizing treatment for patients with RAS-addicted cancers through the discovery, development, and delivery of innovative targeted medicines. Today, we'll begin by highlighting recent progress across our pipeline, beginning with doraxonrasib in pancreatic cancer.
  Nov 6, 2025 - $RVMD